Autism Spectrum Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Autism Spectrum Disorder Treatment Landscape

Several digital health companies are focused on offering autism care while churning favorable returns on investments. The players are involved in strategic partnerships, M&A, funding, and geographical expansions. Los Angeles-based SpectrumAi provides tools that analyze ABA patient therapy outcomes data to improve communication and social and learning skills. The company in 2023 raised USD 20 million in its Series A investment round for autism treatment solutions and services. Other companies in the space comprising Floreo and Sprout, both tech-enabled treatment and autism care players, provide applied behavior-analysis therapy and in-home assessments to its customers. Here are some leading players in the autism spectrum disorder treatment market:

SciSparc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Axial Therapeutics Inc.
Bristol - Myers Squibb Company
Curemark LLC
Eli Lilly and Company
F. Hoffmann - La Roche Ltd.
Johnson & Johnson Services, Inc.
Novartis AG
PaxMedica
Pfizer Inc

Browse Key Market Insights with Data Illustration:

Autism Spectrum Disorder Treatment Market Size Forecasts 2037

In the News

In April 2024, PaxMedica filed a new drug application, or NDA, with the FDA. The firm wanted to emerge into the market, where there are a lot of unmet medical needs. It is anticipated that this tactic will enhance the company's line of business.
In January 2024, SciSparc, an Israeli pharmaceutical company began accepting volunteers for a clinical trial of SCI-210, a drug used to treat children with autism spectrum disorder (ASD). Pediatric ASD patients at Beersheba, Israel's Soroka Medical Center have been recruited by the company.

Frequently Asked Questions (FAQ)

The autism spectrum disorder treatment market size was USD 36.2 billion in 2024.

The global autism spectrum disorder treatment market size was USD 36.2 billion in 2024 and is likely to reach USD 69.1 billion by the end of 2037, expanding at a CAGR of 5.1% over the forecast period, i.e., 2025-2037.

Axial Therapeutics Inc., Bristol - Myers Squibb Company, Curemark LLC, Eli Lilly and Company, F. Hoffmann - La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, PaxMedica, Pfizer Inc are some key players in the market.

The drugs segment is expected to hold a leading share during the forecast period.

North America is projected to offer lucrative prospects with a share of 46.1% during the forecast period.

Autism Spectrum Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Autism Spectrum Disorder Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the autism spectrum disorder treatment market?

What is the outlook for the autism spectrum disorder treatment market?

Who are the major key players dominating the autism spectrum disorder treatment market?

Which solution segment is expected to lead the autism spectrum disorder treatment market by 2037?

Which region will provide more business opportunities for the growth of the autism spectrum disorder treatment market in the future?